- Home
- FMX vs BDX Comparison
FMX vs BDX Comparison
Compare FMX & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMX | BDX |
|---|---|---|
| Founded | 1890 | 1897 |
| Country | Mexico | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1B | 43.0B |
| IPO Year | 1998 | 1998 |
Fundamental Metrics
Financial Performance| Metric | FMX | BDX |
|---|---|---|
| Price | $116.84 | $177.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 13 |
| Target Price | $113.17 | ★ $186.00 |
| AVG Volume (30 Days) | 318.1K | ★ 1.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.30% | 2.89% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.59 |
| Revenue | N/A | ★ $21,840,000,000.00 |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | $8.32 | $3.02 |
| P/E Ratio | ★ $40.94 | $113.08 |
| Revenue Growth | N/A | ★ 8.24 |
| 52 Week Low | $89.54 | $140.11 |
| 52 Week High | $141.47 | $213.08 |
Technical Indicators
Market Signals| Indicator | FMX | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 38.21 | 41.37 |
| Support Level | $116.90 | $153.27 |
| Resistance Level | $118.82 | $192.41 |
| Average True Range (ATR) | 2.36 | 3.72 |
| MACD | -0.06 | -2.42 |
| Stochastic Oscillator | 2.76 | 0.52 |
Price Performance
Historical ComparisonAbout FMX Fomento Economico Mexicano S.A.B. de C.V.
Mexico-based Femsa is a beverage and retail conglomerate in Central and South America. The holding company owns controlling stakes in bottler Coca-Cola Femsa (47% economic stake, 56% voting rights), in addition to operating 100%-owned retail assets, including convenience stores under the Oxxo banner, drugstores, and gas stations. The firm divested its 15% stake in Heineken and its distribution business in 2023. Coca-Cola Femsa and the Oxxo chain made up 75% of total company revenue and over 90% of profits in 2024.
About BDX Becton Dickinson and Company
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.